Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
Sign Up to like & getrecommendations! Published in 2018 at "Biomedicines"
DOI: 10.3390/biomedicines6010026
Abstract: Targeting the immune checkpoint receptors cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death 1 ligand 1 (PD-L1) represents a very attractive treatment modality for tumor patients. The… read more here.
Keywords: ctla inhibitor; prior ctla; inhibitor; treatment ... See more keywords